Oruka Therapeutics (ORKA) Enterprise Value (2010 - 2026)

Oruka Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$831.2 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 138.09% year-over-year to -$831.2 million in Q1 2026; TTM through Mar 2026 was -$831.2 million, a 138.09% decrease from a year earlier, with the FY2025 full-year figure at -$334.9 million, up 10.86% from the prior year.
• Enterprise Value declined to -$831.2 million in Q1 2026 per ORKA's latest filing, from -$334.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$33.3 million in Q2 2024 and bottomed at -$831.2 million in Q1 2026.
• The 5-year median for Enterprise Value is -$46.4 million (2022), against an average of -$222.8 million.
• Across the five-year window, Enterprise Value climbed 26.7% in 2022 and slumped 947.94% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$42.4 million in 2022, then climbed by 11.81% to -$37.4 million in 2023, then sank by 903.57% to -$375.6 million in 2024, then gained by 10.86% to -$334.9 million in 2025, then sank by 148.21% to -$831.2 million in 2026.
• Per Business Quant, the three latest ORKA Enterprise Value figures stand at -$831.2 million (Q1 2026), -$334.9 million (Q4 2025), and -$756.6 million (Q3 2025).